J

Joinn Laboratories China Co Ltd
SSE:603127

Watchlist Manager
Joinn Laboratories China Co Ltd
SSE:603127
Watchlist
Price: 38.87 CNY 0.6% Market Closed
Market Cap: ¥29.1B

P/FCFE

96.8
Current
11%
More Expensive
vs 3-y average of 87.2

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
96.8
=
Market Cap
¥27.7B
/
Free Cash Flow to Equity
¥301m

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
96.8
=
Market Cap
¥27.7B
/
Free Cash Flow to Equity
¥301m

Valuation Scenarios

Joinn Laboratories China Co Ltd is trading above its 3-year average

If P/FCFE returns to its 3-Year Average (87.2), the stock would be worth ¥35.01 (10% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-73%
Maximum Upside
No Upside Scenarios
Average Downside
45%
Scenario P/FCFE Value Implied Price Upside/Downside
Current Multiple 96.8 ¥38.87
0%
3-Year Average 87.2 ¥35.01
-10%
5-Year Average 58.1 ¥23.34
-40%
Industry Average 40.6 ¥16.3
-58%
Country Average 26.4 ¥10.6
-73%

Forward P/FCFE
Today’s price vs future free cash flow to equity

Not enough data available to calculate forward P/FCFE

Peer Comparison

All Multiples
P/FCFE
P/E
All Countries
Close
Market Cap P/FCFE P/E
CN
Joinn Laboratories China Co Ltd
SSE:603127
29.1B CNY 96.8 97.8
US
PerkinElmer Inc
LSE:0KHE
936.1B USD 2 167.8 3 881
US
Thermo Fisher Scientific Inc
NYSE:TMO
174.4B USD 12.2 25.5
US
Danaher Corp
NYSE:DHR
124B USD 19.4 33.6
KR
Samsung Biologics Co Ltd
KRX:207940
82.3T KRW 190.3 46.1
CN
WuXi AppTec Co Ltd
SSE:603259
326.9B CNY 21.5 17.1
CH
Lonza Group AG
SIX:LONN
32.9B CHF -40.7 -119.6
US
Agilent Technologies Inc
NYSE:A
32.4B USD 36.5 25.1
US
Waters Corp
NYSE:WAT
30.1B USD 106.9 46.9
US
IQVIA Holdings Inc
NYSE:IQV
26.8B USD 9.8 19.8
US
Mettler-Toledo International Inc
NYSE:MTD
25.8B USD 31.7 29.7

Market Distribution

Higher than 81% of companies in China
Percentile
81st
Based on 5 086 companies
81st percentile
96.8
Low
0.2 — 13.7
Typical Range
13.7 — 52.8
High
52.8 —
Distribution Statistics
China
Min 0.2
30th Percentile 13.7
Median 26.4
70th Percentile 52.8
Max 2 279 450.9

Joinn Laboratories China Co Ltd
Glance View

Nestled in the bustling heart of China's vibrant biomedical sector, Joinn Laboratories China Co Ltd has emerged as a pivotal player in advancing the field of pharmaceutical research and development. Founded with a vision to revolutionize the landscape of drug testing and safety evaluation, Joinn Laboratories operates as a comprehensive preclinical contract research organization (CRO). The company specializes in providing a wide array of services including toxicology, pharmacology, and bioanalytical testing that are crucial in the early stages of drug development. With an expansive network of state-of-the-art laboratories and a team of highly skilled scientists, Joinn facilitates the essential task of ensuring that pharmaceutical products meet rigorous safety and efficacy standards before advancing to clinical trials. Joinn Laboratories generates revenue primarily by offering these indispensable services to pharmaceutical companies and biotech firms worldwide. By acting as an external testing partner, Joinn allows its clients to significantly streamline their drug development processes, reducing both time and cost associated with bringing a new drug to market. Their business model thrives on the growing demand for outsourced R&D capabilities, a trend fueled by the increasing complexity and regulatory requirements in drug approval processes. The company leverages its expertise and cutting-edge technology to deliver precise and reliable data, thus providing a seamless bridge between scientific discovery and market-ready pharmaceutical solutions.

Intrinsic Value
7.69 CNY
Overvaluation 80%
Intrinsic Value
Price ¥38.87
J
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett